Compass Pathways Surges as BTIG Reaffirms Buy Rating and Trump’s Psychedelic Executive Order Sparks Sector Rally
BTIG raises CMPS to Buy, $14 target; stock jumps 42% after Trump boosts psychedelic research funding and faster FDA paths.
/ 7 items
#ATAI↓
Trump to Launch Federal Research on Psychedelic Drug Ibogaine for PTSD
Trump plans to boost research on ibogaine for PTSD in veterans, despite safety concerns and its illegal status in the US.
Social Anxiety Breakthrough or Overhyped Experiment? AtaiBeckley's R-MDMA Divides Opinion
AtaiBeckley (ATAI) tested an R-MDMA pill for social anxiety. Results looked promising — but the trial was tiny, just 6 weeks, and far from FDA approval.
JonesResearch Starts Coverage on Atai Beckley & Mind Medicine with Buy Ratings
JonesResearch gives Buy ratings to Atai Beckley and Mind Medicine, highlighting potential in psychedelic drug development for depression and anxiety.
Berenberg Rates ATAI Life Sciences Buy with $12 Target on Strong Pipeline
Berenberg maintains Buy rating on ATAI Life Sciences (ATAI) with $12 price target, citing exceptional progress, strong pipeline momentum, and upcoming Phase 3 trials for psychedelic treatments.
Jefferies Boosts Atai Life Sciences Price Target to $10 on FDA Breakthrough Win
Jefferies raises Atai Life Sciences price target to $10 following FDA Breakthrough Therapy Designation for depression drug BPL-003, citing 72% approval rate for BTD drugs.